Myelofibrosis


When Good Cells Go Bad (February 20, 2017)

By Kari Bohlke, ScD Cancer. The word has taken on a meaning that extends beyond the medical definition. Cancer is deadly; it is dangerous; it means bad news. But when we hear the words, “You have cancer,”... Continue Reading

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis (December 20, 2016)

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients... Continue Reading

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia (December 16, 2016)

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American... Continue Reading

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life (October 10, 2016)

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis. Myeloproliferative... Continue Reading

About PCROWD, Dana-Farber’s tissue-banking study for patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes (June 27, 2016)

PCROWD (“Precursor CROWDsourcing”) – a tissue banking and clinical information study and repository – is an indispensable component of the blood cancer research pipeline. The main objective... Continue Reading

Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis (June 7, 2016)

The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual meeting... Continue Reading

MPN Research Foundation Launches CancerConnect Social Media Platform (March 2, 2016)

Austin TX/Sun Valley ID– With the launch of the CancerConnect online community, the MPN Research Foundation (MPNRF) now offers a specialized social network for individuals affected by myeloproliferative... Continue Reading

Year in Review: Myeloproliferative Neoplasms (February 10, 2016)

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening... Continue Reading

MPN Clinical Trial Highlights (August 5, 2015)

Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. Future progress in the treatment of myeloproliferative neoplasms (MPNs) will result from the continued... Continue Reading

Management of Myelofibrosis that Progresses to Acute Myeloid Leukemia (February 22, 2015)

In some patients with myelofibrosis, the condition progresses to a type of leukemia known as acute myeloid leukemia (AML). Information about the management of AML is available here. http://news.cancerconnect.com/acute-myeloid-leukemia/ Strategies... Continue Reading

Diagnosis of Myelofibrosis (February 22, 2015)

Individuals diagnosed with myelofibrosis often have no symptoms. An enlarged spleen or an abnormal blood count may be noticed at a routine check up. Once a diagnosis is suspected additional tests or procedures... Continue Reading

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS